Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-Tau
Biotech
Roche’s Genentech returns Alzheimer’s assets to AC Immune
Genentech is walking away from an 18-year relationship by handing back rights to a pair of Alzheimer’s assets after suffering setbacks in the clinic.
Nick Paul Taylor
Jan 22, 2024 8:47am
Janssen moves 1 of 2 AC Immune Alzheimer's vaccines to next step
Nov 30, 2022 10:40am
TauRx plans Alzheimer's approval filing despite phase 3 failings
Oct 6, 2022 8:00am
J&J's Janssen aims for 'sweet spot' of Alzheimer's R&D
Aug 1, 2022 8:00am
AC Immune, Janssen Alzheimer's vaccine spurs tau antibodies
Feb 15, 2022 9:20am
Sanofi-backed Expansion nabs $80M for RNA neurodegenerative work
Sep 29, 2021 7:00am